Effects of tiapride in tardive dyskinesia.

Tiapride, a selective D2 dopaminergic receptor blocking agent from the substituted benzamide class, was evaluated in a blind video-controlled trial in 10 psychiatric patients with tardive dyskinesia. There was a significant decrease in dyskinesia with a parallel increase in parkinsonism. This relationship between two opposite effects on movement suggests a common pathophysiological basis lying on a reciprocal hyper- and hypoactivity of the dopaminergic striatal system. Nevertheless, other mechanisms may be involved, for the evolution of individual parkinsonian and dyskinesia scores is not necessarily opposite: the tiapride-induced parkinsonism was generally acceptable and in two cases, the dyskinesia scores were reduced without an increase in parkinsonism. Therefore, more dyskinetic patients have to be evaluated in long-term studies with tiapride, before this drug could be recommended in tardive dyskinesia, when dyskinetic movements become intolerable.